Skip to content
Dose Brief
Menu
No. 90 on the board · Grade C

Ivy Rx review

Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

Visit Ivy Rx Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the score.
Semaglutide
From $175/mo (starting dose, compounded)
Tirzepatide
From $275/mo (starting dose, compounded)
Coverage
All 50 states
Brand-name
Compounded only
On the trackerNewnew to the tracker, no prior readingNew to the tracker on 1 August 2026. The published line reads From $175/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

The scorecard

Ivy Rx scored on our six Brief Score factors. See the methodology.

Price Stability48/100
Supply Reliability74/100
Transparency88/100
Access Breadth90/100
Clinical Oversight82/100
Track Record73/100

What we like

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

The caveats

  • Limited public information on program details

The brief

Best for: Readers who want mainstream telehealth GLP-1 access. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

Ranked #90 of 495 providers we reviewed — see our #1 pick, CoreAge Rx, for comparison.

Closest on the board

The desks scoring nearest Ivy Rx — the realistic shortlist if you're weighing it.

Weighing Ivy Rx against one desk in particular? We file it head to head with our top-ranked pick in CoreAge Rx vs Ivy Rx, and every desk that outranks it is listed on the Ivy Rx alternatives board.

More desks we track (24)

464 more are filed too — see every desk we track, ranked.

Pricing, states and verification reflect Ivy Rx's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on Ivy Rx's site. Not medical advice; see our disclosure.

← Back to all rankings